4.7 Article

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 52, Issue 10, Pages 3783-3785

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00473-08

Keywords

-

Funding

  1. National Institute of Health research [5RO1DE018096]
  2. Pfizer and Schering-Plough
  3. Merck, Pfizer, Schering-Plough, and Nektar Therapeutics

Ask authors/readers for more resources

We report a case of Candida glabrata invasive candidiasis that developed reduced susceptibility to caspofungin during prolonged therapy. Pre- and posttreatment isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed an F659V substitution within the FKS2 region of the glucan synthase complex.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available